T. Rowe Price Investment Management
PRME icon

T. Rowe Price Investment Management’s Prime Medicine PRME Stock Holding History

T. Rowe Price Investment Management’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$19.1M Sell
5,481,893
-513,290
-9% -$1.95M 0.01% 471
2025
Q4 		$20.8M Sell
5,995,183
-3,221,914
-35% -$14.3M 0.01% 487
2025
Q3 		$51.1M Buy
9,217,097
+2,732,310
+42% +$11.1M 0.03% 385
2025
Q2 		$16M Buy
6,484,787
+2,341,691
+57% +$3.61M 0.01% 529
2025
Q1 		$8.24M Buy
4,143,096
+165,268
+4% +$422K 0.01% 568
2024
Q4 		$11.6M Buy
3,977,828
+170,541
+4% +$599K 0.01% 546
2024
Q3 		$14.7M Buy
3,807,287
+81,560
+2% +$378K 0.01% 538
2024
Q2 		$19.2M Buy
3,725,727
+635,644
+21% +$3.85M 0.01% 504
2024
Q1 		$21.6M Buy
+3,090,083
New +$23.4M 0.01% 493

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

T. Rowe Price Investment Management's PRME Position: Q1 2026 in Review

T. Rowe Price Investment Management reduced its Prime Medicine (PRME) stake by 8.6% in Q1 2026, selling an estimated $1.95M and leaving 5,481,893 shares worth $19.1M. The position accounts for 0.01% of the portfolio, ranked #471.

T. Rowe Price Investment Management first reported a position in PRME in Q1 2024 and has held it in 9 quarters since. The position peaked at $51.1M in Q3 2025. 192 funds tracked by Wall St. Rank hold PRME as of Q1 2026.

  • T. Rowe Price Investment Management held 5,481,893 shares of Prime Medicine worth $19.1M as of Q1 2026.
  • T. Rowe Price Investment Management sold 513,290 Prime Medicine shares in Q1 2026, an estimated $1.95M.
  • Prime Medicine made up 0.01% of T. Rowe Price Investment Management's portfolio in Q1 2026, its #471 holding.
  • T. Rowe Price Investment Management first reported a position in Prime Medicine in Q1 2024 and has held it in 9 quarters since.
  • T. Rowe Price Investment Management's Prime Medicine position peaked at $51.1M in Q3 2025.
  • 192 funds tracked by Wall St. Rank held Prime Medicine as of Q1 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q1 2026, filed 15 May 2026.